[Immunotherapy based on dendritic cells: from experimentation to clinical development].
Although the DC-based immunotherapy of cancer has been promising in animal models, several questions need to be addressed in depth in humans: the generation of various types of dendritic cells, the analysis of their potential and the immunomonitoring of cancer patients. In our laboratory, our efforts have been focused on (i) the study of the cytotoxic activity of dendritic cells; (ii) the generation of a novel population of human dendritic cells from monocytes cultured in IL-3 and IFN-beta; (iii) the optimisation of the immunostimulatory properties of DC using Fas-ligand surexpression or adjuvants promoting DC/gamma-delta T cell interaction.
Goldman
M
M
Laboratoire d'immunologie expérimentale ULB, Bâtiment G/E, 808, route de Lennik CP 615, 1070, Bruxelles, Belgique. mgoldman@ulb.ac.be <mgoldman@ulb.ac.be>
D000276:Adjuvants, Immunologic; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D053222:Fas Ligand Protein; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology; D007377:Interleukin-3 / Q000494:pharmacology; D008562:Membrane Glycoproteins / Q000276:immunology; D009000:Monocytes / Q000166:cytology / Q000187:drug effects; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination / Q000379:methods*
D000276:Adjuvants, Immunologic; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007377:Interleukin-3; D008562:Membrane Glycoproteins; D016692:Receptors, Antigen, T-Cell, gamma-delta; D016899:Interferon-beta